生化基因 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2025OR TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Commission File Number0-19311 33-0112644(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 225 Binney Street,Cambridge,MA02142(617)679-2000 (Address, including zip code, and telephone number, includingarea code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $0.0005 par valueBIIBThe Nasdaq Global Select Market Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that theregistrant was required to file such reports), and (2)has been subject to such filing requirements for the past90days:Yesx No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data Filerequired to be submitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding12months (or for such shorter period that the registrant was required to submit such files):Yesx Noo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “largeaccelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule12b-2 of the Exchange Act: Accelerated filer☐Smallerreportingcompany☐Emerging growth company☐ Large accelerated filerxNon-acceleratedfiler☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use theextended transition period for complying with any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the ExchangeAct).Yes☐Nox The number of shares of the issuer’s Common Stock, $0.0005par value, outstanding as of April30, 2025,was146,527,832shares. BIOGEN INC.FORM10-Q — Quarterly ReportFor the Quarterly Period Ended March 31, 2025 TABLE OF CONTENTS PARTI—FINANCIAL INFORMATION Item 1.Financial Statements (unaudited)Condensed Consolidated Statements of Income— For the Three Months Ended March 31, 2025 and20248Condensed Consolidated Statements of Comprehensive Income — For the Three Months EndedMarch 31, 2025 and 20249Condensed Consolidated Balance Sheets— As of March 31, 2025 and December31, 202410Condensed Consolidated Statements of Cash Flow— For the Three Months Ended March 31, 2025and 202411Condensed Consolidated Statements of Equity — For the Three Months Ended March 31, 2025 and202412Notes to Condensed Consolidated Financial Statements13Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations44Item 3.Quantitative and Qualitative Disclosures About Market Risk68Item 4.Controls and Procedures70 PARTII—OTHER INFORMATION Item 1.Legal ProceedingsItem1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 5.Other InformationItem 6.ExhibitsSignatures 717187878889 NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements that are being made pursuant to the provisions of the PrivateSecurities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the “SafeHarbor” provisions of the PSLRA. These forward-looking statements may be accompanied by such words as“aim,” “anticipate,” "assume," “believe,” “contemplate,” “continue," "could," “estimate,” “expect,”“forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” "outlook," “plan,”“possible,” "potential," “predict,” “project,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Given their forward-looking nature, these statementsinvolve substantial risks and uncertainties and may be based on inaccurate assumptions. This report includes,among others, forward-looking statements regarding: •our expected financial and operating performance; •our long-term strategy and supporting business plans, including our product pipeline;•our expectations about continued growth through acquisitions and key collaborative relationships andfunding arrangements;•our belief that our long-term competitive position depends upon our success in discovering and developinginnovative, cost-effective products that serve unmet medical needs, along with our ability to manufactureproducts efficiently and to launch and market them effectively in a highly competitive environment;•our ability to obtain and maintain ade